Commonwealth Bank of Australia issues five series of Shield CLNs

Commonwealth Bank of Australia (CBA) is issuing five series of credit-linked notes (CLNs), maturing on September 4, 2006 and referenced on a portfolio of 100 equally weighted investment-grade credits.

The CLNs are issued by Security Holding Investment Entity Linking Deals (Shield), a repackaging vehicle set up by CBA. The CLN Series 11, Series 10, Series 12, Series 13 and Series 14 were rated AAA, AA+, AA, A and BBB, respectively, by credit rating agency Standard & Poor’s, and are worth respectively A$10 million, A$11.5 million, A$120 million, A$10 million and A$15 million.

As part of the transaction, Shield is selling the floating-rate CLNs to investors. Proceeds from the CLNs are invested in “authorised investments” consisting of AAA-rated residential mortgage-backed securities and A-1+ rated short-term securities. Shield is also selling protection on the portfolio of 100 credits to CBA which pays Shield a quarterly swap premium for the credit protection.

At the same time, Shield is entering into a basis swap with CBA, whereby Shield receives a quarterly floating rate interest payment with which it pays the CLN noteholders’ quarterly interest. The basis swap also allows Shield to get protection against market value, re-investment and basis risk on the authorised investments. In return for the basis swap protection, Shield pays CBA the interest payment from its authorised investments.

This is the second series of portfolio CLNs CBA has issued through its Shield vehicle. The first four series, worth a total of A$159.2 million, were issued in June. Shield, which was launched in March this year, has also issued repackaged notes and single-name CLNs.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here